Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
ACCESSWIRE•12/11/2026•09:00 ET
0
Key Highlights
- ➤CYWC628 Phase 1/2 trial expected to enroll up to 120 diabetic foot-ulcer patients
- ➤CYWC628 patient dosing underway, with data expected in 2026
- ➤CYPS317 psoriasis IND under FDA review; 12-week study planned after clearance
- ➤FibroBiologics advancing CYMS101 and CybroCell for multiple sclerosis and disc degeneration
- ➤FibroBiologics reports 325+ issued and pending patents supporting its platform
ORLANDO, FL / ACCESS Newswire / November 12, 2026 / RedChip Companies will host an investor webinar on Thursday, November 19, 2026, at 4:15 p.m. ET with FibroBiologics, Inc. (Nasdaq:FBLG).
The exclusive event will feature Pete O'Heeron, CEO, and Jason Davis, CFO, who will provide an overview of FibroBiologics' strategy to develop off-the-shelf fibroblast-based cell therapies for chronic diseases and regenerative medicine. The Company is advancing a platform designed to harness the regenerative and immune-modulating properties of fibroblasts across multiple indications, including chronic wound care, psoriasis, multiple sclerosis, degenerative disc disease, and thymus regeneration.
Get started
Create a free account to read the full story.